- Home
- ZENV vs ADAG Comparison
ZENV vs ADAG Comparison
Compare ZENV & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- ADAG
- Stock Information
- Founded
- ZENV 2005
- ADAG 2011
- Country
- ZENV Brazil
- ADAG China
- Employees
- ZENV N/A
- ADAG N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- ADAG Health Care
- Exchange
- ZENV Nasdaq
- ADAG Nasdaq
- Market Cap
- ZENV 79.7M
- ADAG 90.8M
- IPO Year
- ZENV 2021
- ADAG 2021
- Fundamental
- Price
- ZENV $1.64
- ADAG $1.69
- Analyst Decision
- ZENV
- ADAG Strong Buy
- Analyst Count
- ZENV 0
- ADAG 2
- Target Price
- ZENV N/A
- ADAG $7.00
- AVG Volume (30 Days)
- ZENV 29.5K
- ADAG 75.8K
- Earning Date
- ZENV 09-04-2025
- ADAG 08-12-2025
- Dividend Yield
- ZENV N/A
- ADAG N/A
- EPS Growth
- ZENV N/A
- ADAG N/A
- EPS
- ZENV N/A
- ADAG N/A
- Revenue
- ZENV $181,911,572.00
- ADAG $103,204.00
- Revenue This Year
- ZENV $6.49
- ADAG $9,289.17
- Revenue Next Year
- ZENV $3.82
- ADAG $36.84
- P/E Ratio
- ZENV N/A
- ADAG N/A
- Revenue Growth
- ZENV 23.99
- ADAG N/A
- 52 Week Low
- ZENV $1.02
- ADAG $1.33
- 52 Week High
- ZENV $3.03
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- ZENV 60.18
- ADAG 43.13
- Support Level
- ZENV $1.48
- ADAG $1.65
- Resistance Level
- ZENV $1.75
- ADAG $2.54
- Average True Range (ATR)
- ZENV 0.10
- ADAG 0.31
- MACD
- ZENV 0.01
- ADAG -0.04
- Stochastic Oscillator
- ZENV 65.00
- ADAG 4.21
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.